Selected Papers of William L. White

Total Page:16

File Type:pdf, Size:1020Kb

Selected Papers of William L. White Selected Papers of William L. White www.williamwhitepapers.com Collected papers, interviews, video presentations, photos, and archival documents on the history of addiction treatment and recovery in America. Citation: White, W. (2014). The early use of chloral hydrate, paraldehyde, chloroform, nitrous oxide and ether for intoxication. Posted at www.williamwhitepapers.com The Use of Chloral Hydrate, Paraldehyde, Chloroform, Nitrous Oxide and Ether for Intoxication William L. White Emeritus Senior Research Consultant Chestnut Health Systems [email protected] NOTE: The original 1,000+ page manuscript for Slaying the Dragon: The History of Addiction Treatment and Recovery in America had to be cut by more than half before its first publication in 1998. This is an edited excerpt that was deleted from the original manuscript. Chloral hydrate was first produced by categories of people who were particularly Justus von Liebig in 1832, although its vulnerable to chloralism: people who took hypnotic and sedative qualities were the drug to relieve chronic pain, alcoholics unknown at that time. These properties who used the drug to help them overcome were discovered by Oscar Liebreich, who sleep problems, and people who were by introduced the drug into medicine in 1869. nature nervous and excitable (Kane, 1881; An ancestor of the modern barbiturates and Abuse of Chloral Hydrate, 1880). eventually replaced by those drugs, chloral Although chloral hydrate was best was known as an excellent soporific (sleep- known to the general public as the "Mickey inducing drug), and at smaller dosages, as a Finn" or the "knock-out drops" of detective Anervous sedative.@ In his 1872 lecture on stories, its primary consumers and abusers chloral hydrate at Rush Medical College, Dr. were middle-class women. Doctors wrote J.H. Etheridge noted that superintendents of that the misuse of chloral was common insane asylums gave chloral high praise for among the most affluent people and its ability to reduce symptoms of insanity observed that "highly organized and (Etheridge, 1872). Many of the 19th-century sensitive people" seemed vulnerable to its secret remedies for nerve troubles gave the influence. Chloral addiction in women unknowing consumer liberal doses of chloral appeared as a theme in early 20th-century (Crothers, 1902). literature, as in Edith Warton’s The House of Reports of chloral hydrate abuse Mirth. It is likely that a wide variety of began to surface in the late 19th and early physical and emotional problems were self- 20th centuries. Its addictive potential was medicated with chloral hydrate during this first reported by Dr. B.W. Richardson of era. An interesting historical footnote about London in 1871. H.H. Kane noted three this drug: Cannabis (marijuana) was williamwhitepapers.com 1 sometimes used during this period to treat intoxication as an element in religious chloral hydrate withdrawal. experience. Paraldehyde, a non-barbiturate liquid Chloroform and ether were also used sedative with a strong odor and bitter taste, as intoxicants in the 1800s. Chloroform was was discovered in 1829 and introduced into developed in 1831 by two men at the same medicine in 1881. It was commonly used in time: Samule Guthrie in America and Justus the treatment of alcoholic withdrawal until it von Liebig in Germany (Grun, 1979). was replaced by barbiturates, and then by Inhaling chloroform as an intoxicant became benzodiazepines. As a withdrawal agent, a fad in the 1850s. Confessional accounts paraldehyde was used to produce sleep and of its use as an intoxicant appeared in to prevent convulsions. Although a few medical journals of the 1880s. These reports of paraldehyde use for intoxication accounts, describing early chloroform did surface over the years--particularly intoxication as “love at first site” and a reports of its misuse by alcoholics, its “heaven of chaste pleasures,” ended with unpleasant smell and taste made it one of tales of the user’s self-deception and the least attractive intoxicants. gradual slide into “chloroformomania” (The Nitrous oxide, popularly known as Chloroform Habit, 1884, p. 251-254). Dr. "laughing gas," was discovered in 1772 by T.D. Crothers noted that women were more the English minister Joseph Priestley, the vulnerable to chloroform addiction than men. same man who invented soda-water. Crothers also noted that most chloroform Nitrous oxide's potential as an anesthetic addicts were former users of alcohol and was first noted in 1799 by Sir Humphry Davy. opium who began to seek relief from delirium Davy was the Superintendent of and insomnia by taking chloroform. He Experiments at the Pneumatic Institution in believed that the power of chloroform Bristol, England, and it was here that we find addiction was every bit as strong as that the first reports of the use of nitrous oxide for associated with other drugs, and that the pleasure. "memory of chloroform narcotism" was Nitrous oxide was introduced into never forgotten by the user (Crothers, 1902, dentistry and surgery by Dr. Horace Wells in p. 287, 296). 1844. The potential for widespread use of Ether was first synthesized by this drug as a surgical anesthetic was set Valerius Cordus of Prussia in 1541 (Nuland, back after Wells made a mistake in 1988), but it wasn't brought to popular calculating the needed dosage. His patient attention until it was rediscovered by the woke up screaming in the middle of a German physician Friedrich Hoffman in surgical demonstration at the 1730. Hoffman christened his liquid form of Massachusetts General Hospital in Boston. ether "anodyne" and recommended it for It is worth noting that Wells became addicted pain. Ether was both drunk and inhaled to chloroform and committed suicide in 1849, enthusiastically in group sprees called "ether after an episode of intoxication in which he frolics." was arrested for running into the street and The use of ether as an intoxicant throwing acid on prostitutes (Nagle, 1968). became particularly popular in Ireland in the Occasional reports of nitrous oxide use for 1840s. Many of the Irish men and women intoxication have popped up from the time who took the alcohol abstinence pledge as the drug was introduced to the present. At part of Father Mathew’s temperance the end of the 19th century, popular campaign were ripe for an intoxicant to newspaper accounts told sensational stories replace the alcohol. Norman Kerr marks the of rich women treating their party guests with local doctor who began prescribing ether in samples of nitrous oxide. (Kandall, 1996, p. water as the beginning of the Irish ether 37) There are also periodic stories of epidemic. Ether’s popularity grew even famous supporters of the drug, like the stronger when the tax on cheap whiskey Harvard psychologist William James, who increased. wrote about the benefits of nitrous oxide williamwhitepapers.com 2 This period in Irish history illustrates when she is deprived of them she two enduring themes in the history of experiences all the cravings that afflict the addiction. The first is that one drug tends to person who dearly loves alcohol and finds be effective as a substitute for another. The himself deprived of it (Greer, Albright & second theme is the likelihood that efforts to Smith, 1915, p. 76). suppress one drug will be followed by increased use of other intoxicants. For The Arsenic Eaters some time, ether competed directly with alcohol for the affections of the Irish. Some Perhaps one of the strangest patterns even preferred ether because of its short- of drug use in the late 19th and early 20th acting effects. If they were arrested for centuries was that of arsenic eating. It public drunkenness, they could be quite seems strange that people could become sober by the time they arrived at the police addicted to eating what is today known as a station proclaiming their innocence (Kerr, poison. But arsenic was used in medicine, 1891). both as a tonic and as a remedy for certain The first popular account of ether disorders (psoriasis, for example). It seems addiction is an 1802 report of Londoner that people began taking arsenic in ever- James Graham. The first medical report on increasing quantities to gain everything from ether addiction was an 1847 Lancet article improved appearance and increased about a gentlemen whose use progressed strength to sexual excitability. Problems so far beyond his control that he needed arose when their tolerance reached toxic "permanent restraint." Later medical reports levels, or when they suddenly stopped using note that the most common forms of damage and went into life-threatening withdrawal. from ether intoxication included gastritis, Lewin's 1931 account of habitual arsenic burns from smoking while using, and death users noted that this pattern was common in from overdose (Nagle, 1968, p. 29). the Southern United States where arsenic Ether and chloroform were also used eaters were called "Dippers" (Lewin, 1931, in surgery and dentistry. Ether was first p. 322). introduced for surgical anesthesia in 1846 by William Morton, who demonstrated its References success at the same hospital that had witnessed Horace Wells’ failure a year Abuse of chloral hydrate (1880). Quarterly earlier. Morton made his discovery based on Journal of Inebriety, 4, 53-54. observations of medical students participating in "ether frolics" (Mikuriya, Crothers, T.D. (1902). The drug habits and 1969, p. 907). Occasional reports of their treatment. Chicago: G.P. Englehard & chloroform and ether fads continued well into Company. the 20th century, their users ranging from young students to high-society matrons in Etheridge, J. (1872). Lectures on chloral search of a novel high. There were also brief hydrate. Chicago Medical Journal, 29, 521- periods of more pervasive use, such as the 527. popular use of cheap sulphuric ether in Wisconsin and Pennsylvania at the turn of Greer, J., Albright, I., and Smith, D.
Recommended publications
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • Anesthetic Barbiturates in Refractory Status Epilepticus
    LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES Anesthetic Barbiturates in Refractory Status Epilepticus G.B. YOUNG, W.T. BLUME, C.F. BOLTON and K.G. WARREN SUMMARY: Two patients with previous INTRODUCTION hours). With intubation and respiratory cerebral damage and seizures and three Generalized status epilepticus is a support an intravenous bolus of 250 mgms. patients with acute inflammatory cerebral medical emergency requiring prompt thiopental was given, followed by 80-120 lesions developed status epilepticus. They mgm/hr. as a continuous infusion for four treatment to prevent cerebral damage days. The seizures stopped promptly. A were unresponsive to standard anticon­ or death. Rapidly acting anticonvuls­ vulsants, but anesthetic barbiturates right-sided hemiparesis resolved over the (thiopental and pentobarbital) stopped the ants such as diazepam, phenytoin or next week and he returned home without seizures promptly. paraldehyde are usually effective. additional neurologicaldeficit. Neurology texts, review articles and Case J. A 41 year old woman developed monographs on epilepsy occasionally measles a week prior to the onset of mention anesthesia for resistant cases. delirium and convulsions. Multi-focal RESUME: Deux patients souffrant pre- Anesthetic barbiturates are less com­ clonic or grand mal seizures continued for alablement de lesion cerebrate et d'epilepsie two days. These were refractory to et trois patients avec lesions cerebrates de monly specified and their effectiveness is not well documented. We present intravenous phenytoin (a loading dose of nature . inflammatoire aigue developpent 1000 mgm intravenously followed by 200 un status epilepticus. Les patients ne five cases successfully treated with mgm every twelve hours), phenobarbital repondent pas a la medication anticon­ anesthetic barbiturates after conven­ (200 mgm intravenous bolus and 60 mgm vulsive standard mais I'emploi de barbitur- tional anticonvulsants failed.
    [Show full text]
  • Toxicological Review of Chloral Hydrate (CAS No. 302-17-0) (PDF)
    EPA/635/R-00/006 TOXICOLOGICAL REVIEW OF CHLORAL HYDRATE (CAS No. 302-17-0) In Support of Summary Information on the Integrated Risk Information System (IRIS) August 2000 U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document may undergo revisions in the future. The most up-to-date version will be made available electronically via the IRIS Home Page at http://www.epa.gov/iris. ii CONTENTS—TOXICOLOGICAL REVIEW for CHLORAL HYDRATE (CAS No. 302-17-0) FOREWORD .................................................................v AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................ vi 1. INTRODUCTION ..........................................................1 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS ..... 2 3. TOXICOKINETICS RELEVANT TO ASSESSMENTS ............................3 4. HAZARD IDENTIFICATION ................................................6 4.1. STUDIES IN HUMANS - EPIDEMIOLOGY AND CASE REPORTS .................................................6 4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS ................................8 4.2.1. Oral ..........................................................8 4.2.2. Inhalation .....................................................12 4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES ..........................13
    [Show full text]
  • Chloral Hydrate and Paraldehyde As Drugs of Addiction
    Sept., 1932J CHLORAL HYDRATE DRUG HABIT : CHOPRA & SINGH CHOPRA 481 certain parts of the Punjab. This is not the outcome of the use of the drug in the treatment Original Articles of insomnia, but is due to entirely different causes. Until a few years ago in that province potable country-made spirits were allowed to CHLORAL HYDRATE AND PARALDE' be sold to retail dealers in bulk and the vendors HYDE AS DRUGS OF ADDICTION bottled the liquor themselves. Some of these ingenious people conceived the idea of diluting R. N. m.d. By CHOPRA, m.a., (Cantab.) the spirit and adding small quantities of chloral I.M.S. LIEUTENANT-COLONEL, hydrate to make up for the loss in its potency and which would result from dilution. The know- GURBAKHSH SINGH CHOPRA, m.b., b.s. ledge that the drug had hypnotic and narcotic was obtained from the (Drug Addiction Inquiry, Indian Research Fund effects undoubtedly Association) medical profession and compounders work- in It was further learnt that Series No. 15 ing dispensaries. the effects chloral hydrate in many Chloral produced by hydrate and paraldehyde belong to resemble those by alcohol, the of ways produced group drugs known as soporifics or especially when the latter is taken in large The chief use of hypnotics. this class of drugs quantities. When the two articles are taken is in the treatment of one insomnia, of the together they act in a manner synergistic to worst evils of modern times from which man- each other and in this way the effect of either kind can suffer.
    [Show full text]
  • Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely Through a Common Mechanism S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/21/mol.117.108290.DC1 1521-0111/91/6/620–629$25.00 https://doi.org/10.1124/mol.117.108290 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:620–629, June 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely through a Common Mechanism s Anita Luethy, James D. Boghosian, Rithu Srikantha, and Joseph F. Cotten Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (A.L., J.D.B., and J.F.C.); Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.); Carver College of Medicine, University of Iowa, Iowa City, Iowa (R.S.) Received January 7, 2017; accepted March 20, 2017 Downloaded from ABSTRACT The TWIK-related acid-sensitive potassium channel 3 (TASK-3; hydrate (165% [161–176]) . 2,2-dichloro- . 2-chloro 2,2,2- KCNK9) tandem pore potassium channel function is activated by trifluoroethanol . ethanol. Similarly, carbon tetrabromide (296% halogenated anesthetics through binding at a putative anesthetic- [245–346]), carbon tetrachloride (180% [163–196]), and 1,1,1,3,3,3- binding cavity. To understand the pharmacologic requirements for hexafluoropropanol (200% [194–206]) activate TASK-3, whereas molpharm.aspetjournals.org TASK-3 activation, we studied the concentration–response of the larger carbon tetraiodide and a-chloralose inhibit. Clinical TASK-3 to several anesthetics (isoflurane, desflurane, sevoflurane, agents activate TASK-3 with the following rank order efficacy: halothane, a-chloralose, 2,2,2-trichloroethanol [TCE], and chloral halothane (207% [202–212]) .
    [Show full text]
  • INF.20/Rev.1
    INF.20/Rev.1 Economic Commission for Europe Inland Transport Committee 17 January 2017 Working Party on the Transport of Dangerous Goods Joint Meeting of Experts on the Regulations annexed to the European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways (ADN) (ADN Safety Committee) Thirteenth session Geneva, 23 - 27 January 2017 Item 5 (b) of the provisional agenda Proposals for amendments to the Regulations annexed to ADN: other proposals Autonome Schutzsysteme Mitteilung von EBU, ESO und ERSTU Ausgangslage Zur 29. Sitzung des Sicherheitsausschusses sind zahlreiche Dokumente vorgelegt worden, die die Anforderungen an Explosionsgruppen für nicht-elektrische Geräte betreffen. Weil es aus Zeitgründen nicht möglich war, im ADN 2017 Änderungen vorzunehmen, hat sich der Sicherheitsausschuss darauf geeinigt, die Probleme in der ersten Phase durch multilaterale Abkommen zu regeln. Hierfür ist das Binnenschifffahrtsgewerbe dankbar. Allerdings verlangt die multilaterale Vereinbarung ADN / M 018 von denjenigen Schiffen, deren Zulassungszeugnis nach dem 31. Dezember 2018 erneuert werden muss, schon sehr bald Maßnahmen, die gründlicher Vorbereitung bedürfen. Aus diesem Grunde ist es erforderlich, sich mit einigen vom Schifffahrtsgewerbe aufgeworfenen Fragen rechtzeitig zu beschäftigen. Frage Im Protokoll der 29. Sitzung des Sicherheitsausschusses ADN/WP.15/AC.2/60 ist unter Ziffer 44. festgehalten worden, dass die informelle Arbeitsgruppe „Stoffe“ mittlerweile um die Prüfung verschiedener Sachverhalte gebeten worden ist. Wie weit sind diese Prüfungen gediehen ? Nachfrage zum Protokolls der 29. Sitzung Im Protokoll der 29. Sitzung des Sicherheitsausschusses ADN/WP.15/AC.2/60 ist unter Ziffer 44. – zweiter Unterpunkt - festgehalten worden, dass das Gewerbe die Arbeitsgruppe Stoffe mit einschlägigen Informationen versorgen müsse. Diese Formulierung des Protokolls bedarf der Nachfrage.
    [Show full text]
  • Oral Chloral Hydrate Compare with Rectal Thiopental in Pediatric Procedural Sedation and Analgesia; a Randomized Clinical Trial
    85 Emergency (2014); 2 (2): 85‐89 ORIGINAL RESEARCH Oral Chloral Hydrate Compare with Rectal Thiopental in Pediatric Procedural Sedation and Analgesia; a Randomized Clinical Trial Reza Azizkhani1, Soheila Kanani1*, Ali Sharifi2, Keihan Golshani1, Babak Masoumi1, Omid Ahmadi1 1. Department of Emergency Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 2. Department of General Surgery, Isfahan University of Medical Sciences, Isfahan, Iran Abstract Introduction: The increasing use of diagnostic imaging in pediatric medicine has resulted in growing need for procedural sedation and analgesia (PSA) to minimize motion artifacts during procedures. The drug of choice in pediatric PSA was not introduced till now. The aim of the present study was comparison of oral chloral hydrate (OCH) and rectal sodium thiopental (RST) in pediatric PSA. Methods: In the present randomized clinical trial, 2‐6 years old pediatrics who referred for performing brain computed tomography scan was enrolled and were randomly divided in to two groups. OCH (50mg/kg) and RST (25mg/kg) were prescribed and a trained nurse recorded the time from drug prescription to receiving the con‐ scious sedation (onset of action), the total time period which the patient has the Ramsay score≥4 (duration of action), and adverse effect of agents. Mann‐Whitney U test and chi‐squared test, and Non‐parametric analysis of covariance (ANCOVA) were used for comparisons. Results: One hundred and forty children were entered to two groups of OCH and RST, randomly. The patients of two groups had similar age, sex, weight, and baseline vital signs except for diastolic blood pressure (p<0.001). The onset of action in OCH and RST groups were 24.5±6.1and 28.7±5.2 minutes, respectively (p<0.001).
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • HS 172 R5/13 Briefly Review the Objectives, Content and Activities of This Session
    HS 172 R5/13 Briefly review the objectives, content and activities of this session. Upon successfully completing this session the participant will be able to: • Explain a brief history of the CNS Depressant category of drugs. • Identify common drug names and terms associated with this category. • Identify common methods of administration for this category. • Describe the symptoms, observable signs and other effects associated with this category. CONTENT SEGMENTS LEARNING ACTIVITIES A. Overview of the Category Instructor-Led Presentations B. Possible Effects Instructor Led Demonstrations C. OtdDtifEfftOnset and Duration of Effects RdiAiReading Assignmen ts D. Overdose Signs and Symptoms Video Presentations E. Expected Results of the Evaluation Slide Presentations F. Classification Exemplar HS 172 R5/13 9-2 • Explain the typical time parameters, i.e. onset and duration of effects, associated with this category. • List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs. • Correctly answer the “topics for study” questions at the end of this session. HS 172 R5/13 9-3 A. Overview of the Category CNS Depressants Central Nervous System Depressants slow down the operations of the brain. Point out that other common names for CNS Depressants are “downers” and “sedative-hypnotics.” • Depressants first affect those arareaseas of the brain that control a person’ s conscious, voluntary actions. • Judgment, inhibitions and reaction time are some of the things that CNS Depressants affect first. • As the dose is increased, depressants begin to affect the parts of the brain that control the body’s automatic processes, heartbeat, respiration, etc.
    [Show full text]
  • Chloral Hydrate Safety Issues
    December 2016 www.nursingcenter.com Chloral Hydrate Safety Issues Chloral hydrate is a sedative-hypnotic that has been associated with serious adverse events in the pediatric population including dosing errors, over-sedation, and administration of the oral liquid by the intravenous (IV) route. In 2012, commercially available chloral hydrate products were discontinued and taken off the market. However, some ambulatory and hospital pharmacies are compounding an oral suspension of chloral hydrate for pediatric sedation in both inpatient and outpatient settings. Section 503A of the Federal Food, Drug and Cosmetic Act permits pharmacists to compound chloral hydrate to provide patient specific prescriptions in limited quantities. Compounded drugs are not approved by the US Food and Drug Administration (FDA), which means the FDA does not verify the safety or effectiveness of compounded drugs. One study found that compared to the commercial formulation, the compounded drug provided a shorter duration of sedation, more frequent need for an additional sedation agent, and frequent sedation failure. Over the last two years, there have been three reported cases of pediatric chloral hydrate overdoses and one death that occurred in the outpatient setting. Respiratory depression and arrest are two serious adverse events that can occur following chloral hydrate administration. Other risks associated with chloral hydrate use include: Resedation after discharge. Chloral hydrate can result in prolonged sedation or resedation with effects lasting longer than 24 hours in children of all ages, even if they appear to have cleared the sedation prior to discharge. Chloral hydrate is converted to trichloroethanol, which has a half-life of up to 66 hours in neonates, 28-40 hours in infants, 8-12 hours in children, and longer following an overdose.
    [Show full text]
  • Chloral Hydrate
    NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDY OF CHLORAL HYDRATE (AD LIBITUM AND DIETARY CONTROLLED) (CAS NO. 302-17-0) IN MALE B6C3F1 MICE (GAVAGE STUDY) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 December 2002 NTP TR 503 NIH Publication No. 03-4437 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NCTR and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals.
    [Show full text]
  • Chloral and Chloral Hydrate 247
    eHLORAL AND CHLORAL HYDRATE 1. Exposure Data 1.1 Chernical and physical data 1.1.1 Nomenclature Chloral Chem. Abstr. Serv. Reg. No.: 75-87-6 Chem. Abstr. Name: Trichloroacetaldehyde IUPAC Systematic Name: Chloral Synonyms: Anhydrous chloral; 2,2,2-trichloroacetaldehyde; trichloroethanal; 2,2,2 trichlo- roethanal Chio rai hydrate Chem. Abstr. Serv. Reg. No.: 302-17-0 Chem. Abstr. Name: 2,2,2- Trichloro-l, l-ethanediol IUPAC Systematic Name: Chloral hydrate Synonyms: Chloral monohydrate; trichloroacetaldehyde hydrate; trichloroacetaldehyde monohydrate; l,l, I-trichloro-2,2-dihydroxyethane 1.1.2 Structural and molecular formulae and relative molecular mass Ci 0 1 ~ CI-C-C L "H CI CiHCl30 Chloral Relative molecular mass: 147.39 Ci OH CI-C-C-H1 1 1 1 Ci OH CiH3Cl30i Chloral hydrate Relative molecular mass: 165.42 -245- 246 IARC MONOGRAPHS VOLUME 63 J.I.3 Chemical and physical properties of the pure substance Chloral (a) Description: Colourless, oily hygroscopic liquid with pungent, irritating odour (Budavari, 1989; EniChem America Inc., 1994) (b) Boilng-point: 97.8 °C (Lide, 1993) (c) Melting-point: -57.5 °C (Lide, 1993) (d) Density: 1.51214 at 20 °C/4 °C (Lide, 1993) (e) Spectroscopy data: Infrared (prism (4626), grating (36780)), ultraviolet (5-3), nuclear magnetic resonance (8241) and mass (814) spectral data have been reported (Sadtler Research Laboratories, 1980; Weast & Astle, 1985). (j Solubility: Soluble in water, carbon tetrachloride, chloroform, diethyl ether and ethanol (Li de, 1993; EniChem America, Inc., 1994) (g) Volatilty: Vapour
    [Show full text]